卡多尼利马布作为免疫治疗耐药状NSCLC的二线治疗:一个病例报告和综述
Shuo Qiu1, Mingtao Shi1, Zhiying Chen1
1Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Frontiers in immunology
|August 8, 2025
概括
卡多尼利马布是一种新型双特异性抗体,对初始免疫疗法耐药的非小细胞肺癌 (NSCLC) 患者显示出有前途. 这种治疗导致部分反应和改善生活质量,表明对免疫疗法耐药NSCLC的潜在新选择.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药物开发 药物开发
背景情况:
- 免疫检查点抑制剂 (ICI) 是高级非小细胞肺癌 (NSCLC) 的标准一线治疗方法.
- 大多数患者对ICI产生耐药性,有效的二线治疗选择有限.
- 针对PD-1和CTLA-4的双特异性抗体cadonilimab显示出潜力,但其在免疫疗法耐药NSCLC中的有效性尚未被探索.
研究的目的:
- 为了评估cadonilimab在患有早期NSCLC的老年患者的疗效,该患者对一线免疫疗法产生了耐药性.
- 评估cadonilimab作为后续线程治疗的临床反应,生活质量和安全性.
主要方法:
- 一位患有早期NSCLC的老年患者的病例报告.
- 在免疫疗法耐药性后使用卡多尼利马布治疗.
- 评估临床反应 (部分反应),呼吸障碍等级 (mMRC),表现状态 (KPS),无进展生存期 (PFS) 和与免疫相关的不良事件 (irAEs).
主要成果:
- 患者在三次卡多尼利马布治疗后获得了部分反应 (PR).
- 症状显著改善:mMRC呼吸障碍等级从3降至1.
- 生活质量改善:KPS得分从60增加到80.
- 无进展生存期 (PFS) 延长至17个月,持续受益.
- 没有报告有临床意义的免疫相关不良事件 (irAEs).
结论:
- 卡多尼利马布在免疫治疗耐药性NSCLC患者中显示出有前途的抗瘤活性和临床益处.
- 双特异性抗体改善了症状,表现状况和生活质量.
- 卡多尼利马布代表了一种潜在的有效后续线治疗选择,用于患有NSCLC的患者,这些患者已经对先前的免疫疗法产生了耐药性.
更多相关视频
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
685
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
